“Appendix 3B New issue announcement, application for quotation of additional securities and agreement” of 19 June, 2018 is posted.
View and download Appendix 3B New issue announcement, application for quotation of additional securities and agreement of 19 June, 2018.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)